Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 13, 2017 - Issue 7
Submit an article Journal homepage
1,317
Views
28
CrossRef citations to date
0
Altmetric
Review

Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury

Industry-led perspective from EFPIA members of the EU Innovative Medicines Initiative Drug Liver Injury Project, MIP DILI

Richard J. WeaverResearch & Biopharmacy, Institut de Recherches Internationales Servier, Suresnes, FranceCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-6439-6030View further author information
ORCID Icon,
Catherine BettsPathology Sciences, Drug Safety and Metabolism, AstraZeneca R&D, Cambridge, UKView further author information
,
Eric A.G. BlommePreclinical Safety, AbbVie, North Chicago, USAView further author information
,
Helga H.J. GeretsNon Clinical Development, Chemin du Foriest, UCB BioPharma SPRL, Braine L’Alleud, BelgiumView further author information
,
Klaus Gjervig JensenDrug ADME Research, H. Lundbeck A/S, 9 Ottiliavej, Valby, DenmarkView further author information
,
Philip G. HewittNon-Clinical Development, Merck KGaA, Darmstadt, GermanyView further author information
,
Satu JuhilaIn Vitro Biology, Orion Pharma, Espoo, FinlandView further author information
,
Gilles LabbeInvestigative Toxicology, Preclinical Safety, Sanofi R&D, Paris, FranceView further author information
,
Michael J. LiguoriPreclinical Safety, AbbVie, North Chicago, USAView further author information
,
Natalie MesensPreclinical Development & Safety, Janssen (Pharmaceutical Companies of Johnson & Johnson) Turnhoutseweg 30, Beerse, BelgiumView further author information
,
Monday O. OgesePathology Sciences, Drug Safety and Metabolism, AstraZeneca R&D, Cambridge, UKView further author information
,
Mikael PerssonInnovative Medicines and Early Clinical Development, Drug Safety and Metabolism, Discovery Safety, AstraZeneca R&D, Mölndal, SwedenView further author information
,
Jan SnoeysPharmacokinetics Dynamics & Metabolism, Janssen (Pharmaceutical Companies of Johnson & Johnson) Turnhoutseweg 30, Beerse, BelgiumView further author information
,
James L. StevensDept of Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USAView further author information
,
Tracy WalkerInvestigative Safety & Drug Metabolism, GlaxoSmithKline, David Jack Centre for Research and Development, Ware, Herts, Hertfordshire, UKView further author information
&
B. Kevin ParkInstitute of Translational Medicine, University of Liverpool, Liverpool, UKView further author information
 show all
Pages 767-782 | Received 08 Jan 2017, Accepted 08 Jun 2017, Published online: 28 Jun 2017

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.